Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Update 2007

Bipolar Disorders

Volumn 8, Issue 6, 2006, Pages 721-739

  Yatham, Lakshmi N ^a   Kennedy, Sidney H ^b   O'donovan, Claire ^c   Parikh, Sagar V ^b   Macqueen, Glenda ^d   Mclntyre, Roger S ^b   Sharma, Verinder ^e   Beaulieu, Serge ^f   Alda, Martin ^c   Baruch, Philippine ^g   Daigneault, Andrea ^h   Milev, Roumen ⁱ   Young, Trevor L ^b   Ravindran, Arun ^b   Schaffer, Ayal ^b   Connoly, Mary ^j   Gorman, Chris P ^k  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITÉ LAVAL   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ QUEEN S UNIVERSITY   (Canada)

^j Mood Disorders Service   (Canada)

^k UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

Bipolar disorder; CANMAT; Depression; Guidelines; Maintenance; Mania; Treatment

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; ICOSAPENTAENOIC ACID; LAMOTRIGINE; LEVOTHYROXINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; OXCARBAZEPINE; PRAMIPEXOLE; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; VERAPAMIL;

ARTICLE; BEHAVIOR THERAPY; BIPOLAR DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DYSLIPIDEMIA; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; HYPERANDROGENISM; HYPERGLYCEMIA; MAINTENANCE THERAPY; MANIA; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE;

ACUTE DISEASE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; BIPOLAR DISORDER; CANADA; COMORBIDITY; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; MOOD DISORDERS; TRIAZINES; VALPROIC ACID;

EID: 34248336316     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2006.00432.x     Document Type: Article

References (160)

1. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 5-69.
2. Simon GE, Ludman EJ, Bauer MS, Unutzer J, Operskalski B. Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry 2006; 63: 500-508.
3. Bauer M, McBride L, Williford W et al. Collaborative care for bipolar disorder, Part II: Impact clinical outcome, function, and costs. Psychiatr Serv 2006; 59: 937-945.
4. Suppes T, Mintz J, McElroy SL et al. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: A sex-specific phenomenon. Arch Gen Psychiatry 2005; 62: 1089-1096.
5. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated 'unipolar'depression re-conceptualized as a depressive mixed state: Implications for the antidepressant-suicide controversy. J Affect Disord 2005; 85: 245-258.
6. Cipriani A, Pretty H, Hawton K, Geddes J. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819.
7. Kessing L, Sondergard L, Kvist K, Andersen P. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62: 860-866.
8. Bowden C, Calabrese J, Swann A et al. Divalproex Sodium, Extended-Release Versus Placebo in the Treatment of Acute Mania. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR186].
9. Khanna S, Vieta E, Lyons B et al. Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 229-234.
10. Gopal S, Steffens D, Kramer M, Olsen M. Symptomatic remission in patients with bipolar mania: Results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005; 66: 1016-1020.
11. Segal S, Riesenberg R, Ice K, English P. Ziprasidone in mania: A 21-day randomized, double-blind, placebo-controlled trial. J Eur Coll Neuropsychopharmacol 2003; 13 (Suppl. 4): 345 [Abstract P.2.152].
12. Potkin S, Keck P, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 301-310.
13. Keck P, Versiani M, Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: A 3-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-748.
14. Ramey T, Murray S, Giller E et al. Ziprasidone efficacy and safety in acute bipolar mania: 12-week study. Eur Neuropsychopharmacol 2005; 15: 440 [Abstract].
15. Hadjakis W, Marcus R, Abou-Gharbia N et al. Aripiprazole in acute mania: results from a second placebo-controlled study. Bipolar Disord 2004; 6 (Suppl.): 39-40 [Abstract 351].
16. Bourin M, Auby P, Marcus R et al. Aripiprazole Versus Haloperidol for Maintained Treatment Effect in Acute Mania. Presented at the 156th American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003 [Abstract NR467].
17. Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536-546.
18. Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripiprazole versus haloperidol in acute bipolar mania: Double-blind, randomized, comparative 12-week trial. Br J Psychiatry 2005; 187: 235-242.
19. Weisler R, Keck P, Swann A et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323-330.
20. Conway C, Chibnall J, Nelson L et al. An open-label trial of adjunctive oxcarbazepine for bipolar disorder. J Clin Psychopharmacol 2006; 26: 95-97.
21. Pratoomsri W, Yatham L, Sohn C, Solomons K, Lam R. Oxcarbazepine add-on in the treatment of refractory bipolar disorder. Bipolar Disord 2005; 7 (Suppl. 5): 37-42.
22. Calabrese J, Bowden C, Sachs G et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
23. Frye M, Ketter T, Kimbrell T et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.
24. Brown E, McElroy S, Keck P et al. A 7-week comparison of olanzapine/ fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025-1033.
25. Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360.
26. Thase M, McCoy R, Chang W, Macfadden W. Efficacy of Quetiapine Monotherapy in Bipolar Depression: A Confirmatory Double-blind, Placebo-controlled Study (The BOLDER II Study). New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR600].
27. Macfadden W, Endicott J, Rajagopalan K, Minkwitz M, Gaddy J. Efficacy of quetiapine in improving quality of life in patients with bipolar depression. Eur Neuropsychopharmacol 2005; 15: 410 [Abstract P.2.044].
28. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
29. Amsterdam J, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression -lack of manic induction. J Affect Disord 2005; 87: 121-130.
30. Schaffer A, Zuker P, Levitt A. Randomized, Double-blind, Pilot Trial Comparing Lamotrigine Versus Citalopram for the Treatment of Bipolar Depression. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR283].
31. Nierenberg A, Ostacher M, Calabrese J et al. Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-216.
32. Calabrese J, Markovitz P, Kimmel S, Wagner S. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12: 53-56.
33. Winsberg M, De Golia S, Strong C, Ketter T. Divalproex therapy in medication-naive and mood stabilizer-naive bipolar II depression. J Affect Disord 2001; 67: 207-212.
34. Davis L, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: A placebo-controlled study. J Affect Disord 2005; 85: 259-266.
35. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomized double-blind placebo-controlled study. Br J Psychiatry 2006; 188: 46-50.
36. Zarate C, Quiroz J, Singh J et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430-432.
37. McIntyre R, Mancini D, McCann S et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord 2002; 4: 207-213.
38. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239.
39. Colom F, Vieta E. Efficacy of Group Psychoeducation in Bipolar Disorders: 5-Year Outcome. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR27].
40. Lam DH, Hayward P, Watkins ER, Wright K, Sham P. Relapse prevention in patients with bipolar disorder: Cognitive therapy outcome after 2years. Am J Psychiatry 2005; 162: 324-329.
41. Scott J, Paykel E, Morriss R et.al. Cognitive-behavioral therapy for severe and recurrent bipolar disorders: Randomized controlled trial. Br J Psychiatry 2006; 188: 313-320.
42. Frank E, Kupfer DJ, Thase ME et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62: 996-1004.
43. Tohen M, Bowden C, Calabrese J et al. Olanzapine Versus Placebo for Relapse Prevention in Bipolar Disorder. Presented at 156th American Psychiatric Association Annual Meeting, San Francisco, CA, May 17-22, 2003 [Abstract NR197].
44. Tohen M, Calabrese J, Sachs G et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256.
45. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290.
46. Ketter T, Houston J, Adams D et al. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry 2006; 67: 95-101.
47. Filovska V, Jackovcevska M, Krsteska R. Lithium and carbamazepin in long-term treatment of bipolar disorder. Eur Neuropsychopharmacol 2005; 15: 634 [Abstract P.8.064].
48. Milev R, Abraham G, Zaheer J. Add-on quetiapine for bipolar depression: a 12-month open-label trial. Can J Psychiatry 2006; S1: 523-530.
49. Hardoy M, Garofalo A, Carpiniello B, Calabrese J, Carta M. Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. Clin Pract Epidemol Ment Health 2005; 1: 7.
50. Pae C, Kim T, Kim J et al. Long-term treatment of adjunctive quetiapine for bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 763-766.
51. Hardoy M, Carta M, Garofalo A, Calabrese J. Quetiapine in long-term add-on therapy of patients with bipolar I disorder inadequately responsive to treatment. Eur Neuropsychopharmacol 2005; 15: 465 [Abstract P.3.025].
52. Baethge C, Baldessarini R, Mathiske-Schmidt K et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005; 66: 174-182.
53. Brown E, Dunner D, Adams D et al. Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Long-term Treatment of Bipolar I Depression. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR189].
54. Vieta E, Goikolea J, Martínez-Arán A et al. Double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006; 67: 473-477.
55. Calabrese J, Suppes T, Bowden C et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841-850.
56. A multicenter, double-blind, placebo-controlled, flexible-dose evaluation of the safety and efficacy of lamotrigine in the long term treatment of subjects who have bipolar disorder with rapid cycling. GlaxoSmithKline Clinical Trial Register. Aug 18, 2005. http://ctr.gsk.co.uk/Summary/lamotrigine/II_SCAB2005.pdf [accessed on 24 Aug 2006].
57. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: A review of its use in bipolar disorder. Drugs 2003; 63: 2029-2050.
58. Calabrese J, Rapport D, Youngstrom E et al. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur Psychiatry 2005; 20: 92-95.
59. Tohen M, Ketter T, Zarate C et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry 2003; 160: 1263-1271.
60. Suppes T, Brown E, Schuh L, Baker R, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc analyses of 47-week data. J Affect Disord 2005; 89: 69-77.
61. Rasgon NL, Altshuler LL, Gudeman D et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: A preliminary report. J Clin Psychiatry 2000; 61: 173-178.
62. O'Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322-330.
63. McIntyre R, Mancini D, McCann S, Srinivasan J, Kennedy S. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003; 5: 28-35.
64. Rasgon NL, Altshuler LL, Fairbanks L et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246-259.
65. Joffe H, Cohen LS, Suppes T et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078-1086.
66. Misri S, Kostaras D, Kostaras X. The use of selective serotonin reuptake inhibitors during pregnancy and lactation: Current knowledge. Can J Psychiatry 2000; 45: 285-287.
67. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28: 137-152.
68. The Health Products and Food Branch. Important safety information on Paxil (paroxetine) and possible increased risk of birth defects. Health, Canada. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/ paxil_3_hpc-cps_e.html [accessed on 12 Oct 2005].
69. Newport DJ, Viguera AC, Beach AJ et al. Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. Am J Psychiatry 2005; 162: 2162-2170.
70. Blackmore E, Jones I, Doshi M et al. Obstetric variables associated with bipolar affective puerperal psychosis. Br J Psychiatry 2006; 188: 32-36.
71. Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disord 2006; 8: 400-404.
72. Wisner KL, Hanusa BH, Peindl KS, Perel JM. Prevention of postpartum episodes in women with bipolar disorder. Biol Psychiatry 2004; 56: 592-596.
73. Findling R, McNamara N, Youngstrom E et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 409-417.
74. Pavuluri M, Henry D, Carbray J, Naylor M, Janicak P. Divalproex sodium for pediatric mixed mania: A 6-month prospective trial. Bipolar Disord 2005; 7: 266-273.
75. Tohen M, Kryzhanovskaya L, Carlson G et.al. Olanzapine in the Treatment of Acute Mania in Adolescents with Bipolar I Disorder: A 3-week, Randomized, Double-blind Placebo-controlled Study. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR291].
76. Biederman J, Mick E, Hammerness P et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005; 58: 589-594.
77. Delbello M, Schwiers M, Rosenberg H, Strakowski S. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216-1223.
78. DelBello MP, Kowatch RA, Adler CM et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45: 305-313.
79. Biederman J, Mick E, Wozniak J et al. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005; 15: 311-317.
80. Biederman J, Mick E, Wozniak J et al. A prospective open-label long-term treatment trial of risperidone monotherapy in children and adolescents with bipolar disorder. Eur Neuropsychopharmacol 2005; 15: 602 [Abstract P.7.024].
81. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005; 20: 603-610.
82. Biederman J, McDonnell MA, Wozniak J et al. Aripiprazole in the treatment of pediatric bipolar disorder: A systematic chart review. CNS Spectr 2005; 10: 141-148.
83. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 298-304.
84. Delbello MP, Findling RL, Kushner S et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 539-547.
85. Barzman DH, DelBello MP, Kowatch RA et al. Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005; 15: 931-937.
86. Hah M, Chang K. Atomoxetine for the treatment of attention-deficit hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005; 15: 996-1004.
87. Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: Results from an epidemiological community sample. Am J Psychiatry 2006; 163: 319-321.
88. Gildengers AG, Mulsant BH, Begley AE et al. A pilot study of standardized treatment in geriatric bipolar disorder. Am J Geriatr Psychiatry 2005; 13: 319-323.
89. Salloum I, Cornelius J, Daley D et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62: 37-45.
90. Beyer J, Kuchibhatla M, Gersing K, Krishnan KR. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology 2005; 30: 401-404.
91. Kilbourne A, Cornelius J, Han X et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004; 6: 368-373.
92. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: Epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17: 83-93.
93. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-850.
94. Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord 1987; 13: 287-292.
95. Fenn HH, Bauer MS, Altshuler L et al. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. J Affect Disord 2005; 86: 47-60.
96. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64: 1426-1435.
97. McIntyre R, Konarski J, Yatham L. Comorbidity in bipolar disorder: A framework for rational treatment selection. Hum Psychopharmacol 2004; 19: 369-386.
98. McElroy SL. Diagnosing and treating comorbid (complicated) bipolar disorder. J Clin Psychiatry 2004; 65 (Suppl. 15): 35-44.
99. Sajatovic M. Bipolar disorder: Disease burden. Am J Manag Care 2005; 11: 80-84.
100. Calabrese J, Hirschfeld R, Reed M et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry 2003; 64: 425-432.
101. Matthews A, Hauser P. Hepatitis C Testing, Infection, and Treatment Rates among Patients with Bipolar Disorder and Substance Use Disorders. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR249].
102. Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 2003; 73: 261-269.
103. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004; 75: 1662-1666.
104. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994; 31: 91-96.
105. Harris E, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53.
106. Cassidy F, Ahearn E, Carroll B. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-1420.
107. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26.
108. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
109. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424-430.
110. D'Mello D, Narang S, Agredano G. The Prevalence and Clinical Consequences of the Metabolic Syndrome in Patients with Bipolar Disorder. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR201].
111. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
112. NCEP. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
113. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
114. McIntyre R, Konarski J, Wilkins K, Soczynska J, Kennedy S. Obesity in bipolar disorder and major depressive disorder: Results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51: 274-280.
115. McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63: 207-213.
116. Fagiolini A, Frank E, Houck P et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63: 528-533.
117. Heart and Stroke Foundation of Canada. The growing burden of heart disease and stroke in Canada. 2003 http://www.cvdinfobase.ca/cvdbook [accessed on 20 June 2003].
118. Fagiolini A, Kupfer D, Houck P, Novick D, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160: 112-117.
119. Mahmood T, Romans S, Silverstone T. Prevalence of migraine in bipolar disorder. J Affect Disord 1999; 52: 239-241.
120. Fasmer O. The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalalgia 2001; 21: 894-899.
121. McIntyre R, Konarski J, Wilkins K et al. The prevalence and impact of migraine headache in bipolar disorder: Results from the Canadian community health survey. Headache 2006; 26: 1-10.
122. Low NC, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache 2003; 43: 940-949.
123. Fasmer OB, Oedegaard KJ. Clinical characteristics of patients with major affective disorders and comorbid migraine. World J Biol Psychiatry 2001; 2: 149-155.
124. Morriss R, Mohammed FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol 2005; 19: 94-101.
125. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999; 50: 1303-1308.
126. Sachs G, Bowden C, Calabrese JR et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8: 175-181.
127. Yoon B, Bae A, Sea Y, Kim J, Kim M. Combination of topiramate in acute mania. Eur Neuropsychopharmacol 2005; 15: 440 [Abstract P.2.212].
128. McIntyre R, Riccardelli R, Binder C, Kusumakar V. Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 2005; 50: 415-422.
129. Vieta E, Sanchez-Moreno J, Goikolea J et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004; 24: 374-378.
130. Baptista T, Martinez J, Lacruz A et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Can J Psychiatry 2006; 51: 192-196.
131. Ahrens B, Grof P, Moller HJ, Muller-Oerlinghausen B, Wolf T. Extended survival of patients on long-term lithium treatment. Can J Psychiatry 1995; 40: 241-246.
132. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: A 40-44-year follow-up. Arch Suicide Res 2005; 9: 279-300.
133. Mathew N. Antiepileptic drugs in migraine prevention. Headache 2001; 41 (Suppl. 1): 18-24.
134. Meinhold JM, Blake LM, Mini LJ et al. Effect of divalproex sodium on behavioral and cognitive problems in elderly dementia. Drugs Aging 2005; 22: 615-626.
135. Deberdt WG, Dysken MW, Rappaport SA et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 13: 722-730.
136. Burmeister JE, Pereira RR, Hartke EM, Kreuz M. Topiramate and severe metabolic acidosis: Case report. Arq Neuropsiquiatr 2005; 63: 532-534.
137. Groeper K, McCann ME. Topiramate and metabolic acidosis: A case series and review of the literature. Paediatr Anaesth 2005; 15: 167-170.
138. Ozer Y, Altunkaya H. Topiramate induced metabolic acidosis. Anaesthesia 2004; 59: 830.
139. Ko CH, Kong CK. Topiramate-induced metabolic acidosis: Report of two cases. Dev Med Child Neurol 2001; 43: 701-704.
140. Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004; 41: 166-169.
141. Takhar J, Manchanda R. Nephrolithiasis on topiramate therapy. Can J Psychiatry 2000; 45: 491-493.
142. Kuo RL, Moran ME, Kim DH et al. Topiramate-induced nephrolithiasis. J Endourol 2002; 16: 229-231.
143. Alore PL, Jay WM, Macken MP. Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective. Semin Ophthalmol 2006; 21: 15-17.
144. Mansoor Q, Jain S. Bilateral angle-closure glaucoma following oral topiramate therapy. Acta Ophthalmol Scand 2005; 83: 627-628.
145. Hilton EJ, Hosking SL, Betts T. The effect of antiepileptic drugs on visual performance. Seizure 2004; 13: 113-128.
146. Cilli AS, Algun E. Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone. J Clin Psychiatry 2002; 63: 742.
147. Vieta E, Suppes T, Raines S, Macfadden W. Quetiapine for the treatment of bipolar II depression. Eur Neuropsychopharmacol 2005; 15: 421 [Abstract P.2.069].
148. Hirschfeld R, Suppes T, Vieta E et al. Quetiapine Monotherapy for Bipolar II Depression: Pooled Results from two Placebo-controlled Studies. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR227].
149. Amsterdam J, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005; 20: 257-264.
150. Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163: 272-275.
151. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486-491; quiz 92-93.
152. Gianfrancesco F, Pesa J, Wang RH, Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design. Am J Health Syst Pharm 2006; 63: 431-441.
153. Emsley R, Turner HJ, Schronen J et al. Effects of quetiapine and haloperidol on body mass index and glycemic control: A long-term, randomized, controlled trial. Int J Neuropsychopharmacol 2005; 8: 175-182.
154. Sumiyoshi T, Roy A, Anil AE et al. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: A survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol 2004; 24: 345-348.
155. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
156. Canadian Diabetes Association. Canadian Diabetes Association, 2003 Clinical Practice Guideline for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003; http://www.diabetes.ca/cpg2003/ default.aspx [accessed on 23 October 2006].
157. Gergerlioglu HS, Savas HA, Celik A et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology 2006; 53: 108-112.
158. L'Italien G, Newcomer J, Tuomari V et al. Dyslipidemia Risk Differs According to Atypical Antipsychotic Use: A Review and Meta-analysis. New Research Abstracts, Annual Meeting of the American Psychiatric Association, Toronto, May 20-25, 2006 [Abstract NR392].
159. Meltzer H. The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: Are there differences? Int J Neuropsychopharmacol 2005; 8: 153-156.
160. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169: 921-924.